Box Office: ‘Michael’ Moonwalks to $12.6 Million in Previews, Beating ‘Project Hail Mary’ for Biggest of the Year

"Michael" is tracking to open at $65 million to $75 million domestically, with some exhibitors seeing as much as $80 million, after taking in $12.6 million in North American previews and $18.5 million on opening day in foreign markets. Global box office is projected at $140 million to $150 million by Sunday, despite poor reviews and costly reshoots that pushed production costs to at least $170 million. The strong opening would make it a record start for a musical biopic, ahead of "Bohemian Rhapsody" and "Straight Outta Compton."

Analysis

The market is re-pricing a binary outcomes story into a favorable asymmetric setup: near-term box office strength can de-risk a very large fixed-cost slate, but the real incremental value is not the opening weekend itself — it is the probability of a durable international tail and downstream ancillary monetization. For a distributor with limited balance-sheet slack, a strong launch can matter disproportionately because it improves financing terms for future projects and increases negotiating leverage with exhibitors, especially if occupancy remains elevated after the fan-driven opening burst fades.

The second-order winner is likely the broader premium theatrical ecosystem rather than the film’s direct economics. A record musical-biopic opening would reinforce that “eventized” adult-skewing content can still pull audiences back into cinemas, which supports concession revenue, premium-format utilization, and the release calendar economics for exhibitors. That creates relative upside for theater chains versus the broader media complex, even if studio margins on this title remain capped by the inflated production base.

The main risk is that consensus may be extrapolating opening-weekend demand into profitability too aggressively. At this cost structure, the film likely needs an exceptional global multiplier and robust post-theatrical monetization to earn back capital efficiently; if audience legs normalize after the first 72 hours, the headline gross can look strong while equity value creation remains modest. The legal-sensitive subject matter also leaves room for review volatility, negative publicity, or international territory-specific underperformance to compress the back-half forecast.

Contrarian takeaway: the crowded “box office beat = bullish studio” narrative may be underestimating how much of the upside leaks to exhibitors, premium screens, and downstream distribution partners, while the studio still bears most of the production overrun risk. The cleaner trade is not to chase the headline hit, but to own the part of the value chain that benefits from a broader re-rating in theatrical demand without carrying the film-specific budget overhang.

Key Decisions for Investors

• Long AMC or CNK into the next 1-2 weeks as a tactical trade on premium-format demand and concession leverage; risk/reward is favorable if weekend-to-weekday drops are contained, with stop-loss on signs of weak second-week holds.
• Avoid chasing long LION/Lionsgate on the headline opening alone; if anything, use strength to fade on the premise that the capital intensity and reshoot overrun leave limited residual equity upside unless legs and international turnout surprise materially.
• Pair trade: long exhibition basket (AMC/CNK) vs short a broad media basket or studio proxy over the next 1-3 months to express the view that theatrical recovery accrues more to the cinema layer than to the film financier.
• If options liquidity allows, buy short-dated calls on AMC/CNK and finance partially by selling longer-dated upside in the same names, expressing a near-term demand spike with limited conviction on multi-quarter durability.
• Set a catalyst watch for the second-weekend hold and overseas rollout data; if domestic drop exceeds ~55% or international markets underdeliver, rotate out of exhibition longs quickly because the narrative changes from ‘event film’ to ‘front-loaded fan turnout.’